US FDA APPROVES QBIOTICS INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE TIGILANOL TIGLATE SOFT TISSUE SARCOMA PHASE II TRIAL apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ QBiotics Group Limited (QBiotics), a life sciences company developing novel small molecule oncology and wound healing pharmaceuticals, has been.
/PRNewswire/ QBiotics Group Limited (QBiotics), a life sciences company developing novel small molecule oncology and wound healing pharmaceuticals, has been.
QBiotics Group Limited (QBiotics), a life sciences company developing novel small molecule anticancer and wound healing pharmaceuticals, is pleased to announce that it has dosed the first patient in the Phase Ib/IIa clinical trial of the company's lead oncology molecule, tigilanol tiglate in combination with MSD's immune checkpoint inhibitor KEYTRUDA® (pembrolizumab) for patients with unresectable melanoma, the deadliest form of skin cancer.